{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:13:39Z","timestamp":1794561219373,"version":"4.9.1"},"reference-count":102,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.survophthal.2021.02.012","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T12:33:17Z","timestamp":1614688397000},"page":"877-891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1774-4375","authenticated-orcid":false,"given":"Hao","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6541-2028","authenticated-orcid":false,"given":"Patricia","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2137-8339","authenticated-orcid":false,"given":"Tamorah","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Ostmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7964-9475","authenticated-orcid":false,"given":"John Peter","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0001","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1542\/peds.2008-2816","article-title":"Meta-analysis of neurobehavioral outcomes in very preterm and\/or very low birth weight children","volume":"124","author":"Aarnoudse-Moens","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0002","series-title":"The Capute Scales. Cognitive Adaptive Test\/Clinical Linguistic & Auditory Milestone Scale","author":"Accardo","year":"2005"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0003","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3928\/23258160-20200326-03","article-title":"Neurodevelopmental Outcomes Following Intravitreal Bevacizumab With Laser Versus Laser Photocoagulation Alone for Retinopathy of Prematurity","volume":"51","author":"Ahmed","year":"2020","journal-title":"Ophthalmic Surgery, Lasers and Imaging Retina"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fmed.2016.00021","article-title":"Aberrant pulmonary vascular growth and remodeling in bronchopulmonary dysplasia","volume":"3","author":"Alvira","year":"2016","journal-title":"Frontiers in Medicine"},{"issue":"3","key":"10.1016\/j.survophthal.2021.02.012_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S0749-3797(02)00655-4","article-title":"The effectiveness of early childhood development programs. A systematic review","volume":"24","author":"Anderson","year":"2003","journal-title":"Am J Prev Med"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0006","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1076\/chin.8.2.71.8724","article-title":"Assessment and development of executive function (EF) during childhood","volume":"8","author":"Anderson","year":"2002","journal-title":"Child Neuropsychology"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0007","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13854046.2016.1216518","article-title":"Assessing developmental delay in early childhood\u2014concerns with the Bayley-III scales","volume":"31","author":"Anderson","year":"2017","journal-title":"Clin Neuropsychol"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0008","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jpeds.2017.04.059","article-title":"Associations of newborn brain magnetic resonance imaging with long-term neurodevelopmental impairments in very preterm children","volume":"187","author":"Anderson","year":"2017","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.survophthal.2021.02.012_bib0009","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"Araz-Ersan","year":"2015","journal-title":"Curr Eye Res"},{"issue":"3","key":"10.1016\/j.survophthal.2021.02.012_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230678","article-title":"Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity","volume":"15","author":"Arima","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.survophthal.2021.02.012_bib0011","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.survophthal.2021.02.012_bib0012","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/01.DBP.0000452240.39511.d4","article-title":"Neurodevelopmental outcomes of infants born prematurely","volume":"35","author":"Aylward","year":"2014","journal-title":"Journal of Developmental & Behavioral Pediatrics"},{"issue":"3","key":"10.1016\/j.survophthal.2021.02.012_bib0013","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clp.2018.05.007","article-title":"Public health implications of very preterm birth","volume":"45","author":"Barfield","year":"2018","journal-title":"Clin Perinatol"},{"issue":"5","key":"10.1016\/j.survophthal.2021.02.012_bib0014","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaapos.2019.05.013","article-title":"Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab","volume":"23","author":"Barry","year":"2019","journal-title":"Journal of American Association for Pediatric Ophthalmology and Strabismus"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2020.06.002","article-title":"A comparison of respiratory outcomes after treating retinopathy of prematurity with laser photocoagulation or intravitreal bevacizumab","author":"Barry","year":"2020","journal-title":"Ophthalmology Retina"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0016","unstructured":"Bayley N, Aylward GP. Bayley Scales of Infant and Toddler Development (Bayley 4). Pearson."},{"issue":"5","key":"10.1016\/j.survophthal.2021.02.012_bib0017","first-page":"346","article-title":"Retinopathy of prematurity and neurodevelopmental disabilities in premature infants","volume":"20","author":"Beligere","year":"2015","journal-title":"InSeminars in Fetal and Neonatal Medicine"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0018","doi-asserted-by":"crossref","DOI":"10.1177\/1053815120921946","article-title":"Executive function in infants and toddlers born low birth weight and preterm","author":"Blasco","year":"2020","journal-title":"Journal of Early Intervention"},{"issue":"S1","key":"10.1016\/j.survophthal.2021.02.012_bib0019","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"issue":"9","key":"10.1016\/j.survophthal.2021.02.012_bib0020","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/DBP.0000000000000110","article-title":"Predictive validity of the Bayley, at 2 years for intelligence quotient at 4 years in preterm infants","volume":"35","author":"Bode","year":"2014","journal-title":"Journal of Developmental & Behavioral Pediatrics"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0021","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2105\/AJPH.2014.302008","article-title":"The role of socioeconomic factors in Black\u2013White disparities in preterm birth","volume":"105","author":"Braveman","year":"2015","journal-title":"Am J Public Health"},{"issue":"1","key":"10.1016\/j.survophthal.2021.02.012_bib0022","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/IYC.0b013e3181c816cc","article-title":"Developmental screening measures: Stretching the use of the ASQ for other assessment purposes","volume":"23","author":"Bricker","year":"2010","journal-title":"Infants & Young Children"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0023","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/87565641.2018.1564310","article-title":"Beyond the Bayley: neurocognitive assessments of development during infancy and toddlerhood","volume":"44","author":"Brito","year":"2019","journal-title":"Dev Neuropsychol"},{"issue":"5","key":"10.1016\/j.survophthal.2021.02.012_bib0024","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/dmcn.13685","article-title":"Cognitive outcomes in children and adolescents born very preterm: a meta-analysis","volume":"60","author":"Brydges","year":"2018","journal-title":"Developmental Medicine & Child Neurology"},{"issue":"1","key":"10.1016\/j.survophthal.2021.02.012_bib0025","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-1958","article-title":"Victorian Infant Collaborative Study Group. Trends in executive functioning in extremely preterm children across 3 birth eras","volume":"141","author":"Burnett","year":"2018","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0026","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/02713683.2016.1164190","article-title":"Histological and immunohistochemical retinal changes following the intravitreal injection of aflibercept, bevacizumab and ranibizumab in newborn rabbits","volume":"42","author":"Cam","year":"2017","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0027","series-title":"Minnesota Executive Function Scale: Test Manual","author":"Carlson","year":"2014"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0028","unstructured":"Centers for Disease Control. (2017, June). Preterm birth. Retrieved from Centers for Disease Control, Reproductive Health, Maternal and Infant Health, June 16, 2017."},{"issue":"10","key":"10.1016\/j.survophthal.2021.02.012_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223972","article-title":"Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment","volume":"14","author":"Chang","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/MOP.0b013e3283423f35","article-title":"Current update on retinopathy of prematurity: screening and treatment","volume":"23","author":"Chen","year":"2011","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0031","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3928\/23258160-20180129-07","article-title":"Outcomes of Intravitreal Bevacizumab and Diode laser photocoagulation for treatment-warranted retinopathy of prematurity","volume":"49","author":"Chen","year":"2018","journal-title":"Ophthalmic Surgery, Lasers and Imaging Retina"},{"issue":"6","key":"10.1016\/j.survophthal.2021.02.012_bib0032","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.survophthal.2021.02.012_bib0033","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1167\/iovs.17-22431","article-title":"Systemic biodistribution and intravitreal pharmacokinetic properties of bevacizumab, ranibizumab, and aflibercept in a nonhuman primate model","volume":"58","author":"Christoforidis","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.survophthal.2021.02.012_bib0034","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1542\/peds.81.5.697","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results","volume":"81","year":"1988","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.survophthal.2021.02.012_bib0035","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Archives of Ophthalmology (Chicago, Ill.: 1960)"},{"issue":"1","key":"10.1016\/j.survophthal.2021.02.012_bib0036","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1017\/S1355617708080053","article-title":"Executive functioning in preschool children born very preterm: relationship with early white matter pathology","volume":"14","author":"Edgin","year":"2008","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0037","series-title":"Contemporary intellectual assessment: Theories, tests, and issues","article-title":"The differential ability scales\u2014second edition","author":"Elliott","year":"2018"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0038","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/APO.0000000000000302","article-title":"Update on anti-vascular endothelial growth factor safety for retinopathy of prematurity","volume":"9","author":"Enr\u00edquez","year":"2020","journal-title":"The Asia-Pacific Journal of Ophthalmology"},{"issue":"11","key":"10.1016\/j.survophthal.2021.02.012_bib0039","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","article-title":"Neurodevelopmental outcomes after Intravitreal Bevacizumab therapy for retinopathy of prematurity","volume":"126","author":"Fan","year":"2019","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.survophthal.2021.02.012_bib0040","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.9.8.43","article-title":"Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial","volume":"9","author":"Fidler","year":"2020","journal-title":"Translational Vision Science & Technology"},{"issue":"6","key":"10.1016\/j.survophthal.2021.02.012_bib0041","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3061","article-title":"American Academy of Pediatrics Section on Ophthalmology. Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0042","series-title":"Peabody Developmental Motor Scales","author":"Folio","year":"2000"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0043","series-title":"Ages & Stages Questionnaires","author":"Frankenburg","year":"2009"},{"issue":"11","key":"10.1016\/j.survophthal.2021.02.012_bib0044","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial: A randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"Gilbert","year":"2008","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0046","series-title":"Behavior Rating Inventory of Executive Function, Preschool Version (BRIEF-P)","author":"Gioia","year":"2003"},{"issue":"6","key":"10.1016\/j.survophthal.2021.02.012_bib0047","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.survophthal.2021.02.012_bib0048","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0049","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.clp.2014.08.011","article-title":"Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity","volume":"41","author":"Hartnett","year":"2014","journal-title":"Clin Perinatol"},{"issue":"9","key":"10.1016\/j.survophthal.2021.02.012_bib0050","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","article-title":"Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection","volume":"35","author":"Hong","year":"2015","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.survophthal.2021.02.012_bib0051","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0052","series-title":"The guide of Kyoto Scale of psychological development","author":"Ikuzawa","year":"2001"},{"issue":"5","key":"10.1016\/j.survophthal.2021.02.012_bib0053","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jaapos.2014.07.159","article-title":"Effect of laser photocoagulation on plasma levels of VEGF-A, VEGFR-2, and Tie2 in infants with retinopathy of prematurity","volume":"18","author":"Imamoglu","year":"2014","journal-title":"Journal of American Association for Pediatric Ophthalmology and Strabismus"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0054","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.infbeh.2016.07.004","article-title":"Paths of cognitive and language development in healthy preterm infants","volume":"44","author":"Ionio","year":"2016","journal-title":"Infant Behavior and Development"},{"issue":"12","key":"10.1016\/j.survophthal.2021.02.012_bib0055","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0056","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/NNR.0000000000000360","article-title":"Poverty, Toxic Stress, and Education in Children Born Preterm","volume":"68","author":"Kelly","year":"2019","journal-title":"Nurs Res"},{"issue":"1","key":"10.1016\/j.survophthal.2021.02.012_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"Journal of American Association for Pediatric Ophthalmology and Strabismus"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0058","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2021.02.012_bib0059","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12886-018-0685-6","article-title":"Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)","volume":"18","author":"Li","year":"2018","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2021.02.012_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.survophthal.2021.02.012_bib0061","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamapediatrics.2015.2175","article-title":"Prognostic factors for poor cognitive development in children born very preterm or with very low birth weight: a systematic review","volume":"169","author":"Linsell","year":"2015","journal-title":"JAMA Pediatrics"},{"issue":"7","key":"10.1016\/j.survophthal.2021.02.012_bib0062","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3928\/23258160-20170630-06","article-title":"The epidemiology of retinopathy of prematurity in the United States","volume":"48","author":"Ludwig","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0063","unstructured":"Martin JA, Hamilton BE, Osterman M, Driscoll AK, Mathews TJ. Births: Final Data for 2018. Hyattsville, MD: National Center for Health Statistics, CDC."},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0064","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Mart\u00ednez-Castellanos","year":"2013","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.survophthal.2021.02.012_bib0065","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.survophthal.2021.02.012_bib0066","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1006\/cogp.1999.0734","article-title":"The unity and diversity of executive functions and their contributions to complex \u201cfrontal lobe\u201d tasks: A latent variable analysis","volume":"41","author":"Miyake","year":"2000","journal-title":"Cognit Psychol"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0067","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.survophthal.2021.02.012_bib0068","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1542\/peds.106.5.998","article-title":"Severity of neonatal retinopathy of prematurity is predictive of neurodevelopmental functional outcome at age 5.5 years","volume":"106","author":"Msall","year":"2000","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0069","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-0933","article-title":"Survival and impairment of extremely premature infants: a meta-analysis","volume":"143","author":"Myrhaug","year":"2019","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0070","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.survophthal.2021.02.012_bib0071","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/0002-9394(52)91140-9","article-title":"Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations","volume":"35","author":"Patz","year":"1952","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2021.02.012_bib0072","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1043","article-title":"Behavioral problems and socioemotional competence at 18 to 22 months of extremely premature children","volume":"139","author":"Peralta-Carcelen","year":"2017","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0073","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0057","article-title":"Concerns for development after bevacizumab treatment of ROP","volume":"137","author":"Quinn","year":"2016","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.survophthal.2021.02.012_bib0074","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41372-019-0420-z","article-title":"Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser","volume":"39","author":"Raghuram","year":"2019","journal-title":"J Perinatol"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0075","series-title":"Essentials of WPPSI-IV assessment","author":"Raiford","year":"2014"},{"issue":"6","key":"10.1016\/j.survophthal.2021.02.012_bib0076","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3928\/23258160-20190605-01","article-title":"Neurodevelopmental Outcomes Comparing Bevacizumab to Laser for Type 1 ROP","volume":"50","author":"Rodriguez","year":"2019","journal-title":"Ophthalmic Surgery, Lasers and Imaging Retina"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0077","first-page":"497","article-title":"Early neurodevelopmental outcomes of extremely preterm infants","volume":"40","author":"Rogers","year":"2016"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0078","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.intell.2011.03.003","article-title":"Basic information processing abilities at 11 years account for deficits in IQ associated with preterm birth","volume":"39","author":"Rose","year":"2011","journal-title":"Intelligence"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0079","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1469-8749.2008.02045.x","article-title":"Development of the gross motor function classification system for cerebral palsy","volume":"50","author":"Rosenbaum","year":"2008","journal-title":"Developmental Medicine & Child Neurology"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0081","series-title":"Vineland Adaptative Behavior Scales, (VABS 3)","author":"Sparrow","year":"2016"},{"issue":"9","key":"10.1016\/j.survophthal.2021.02.012_bib0082","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/CHI.0b013e3181af8235","article-title":"Early emergence of behavior and social-emotional problems in very preterm infants","volume":"48","author":"Spittle","year":"2009","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"6","key":"10.1016\/j.survophthal.2021.02.012_bib0083","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-2719","article-title":"Cognitive development and quality of life associated with BPD in 10-year-olds born preterm","volume":"141","author":"Sriram","year":"2018","journal-title":"Pediatrics"},{"issue":"10208","key":"10.1016\/j.survophthal.2021.02.012_bib0084","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet North Am Ed"},{"issue":"9","key":"10.1016\/j.survophthal.2021.02.012_bib0085","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jamaophthalmol.2019.2433","article-title":"Monitoring disease progression with a quantitative severity scale for retinopathy of prematurity using deep learning","volume":"137","author":"Taylor","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0086","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/jcpp.12001","article-title":"Practitioner review: Do performance-based measures and ratings of executive function assess the same construct?","volume":"54","author":"Toplak","year":"2013","journal-title":"Journal of child psychology and psychiatry"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0087","doi-asserted-by":"crossref","first-page":"F419","DOI":"10.1136\/archdischild-2018-315028","article-title":"Academic trajectories of very preterm born children at school age","volume":"104","author":"Twilhaar","year":"2019","journal-title":"Archives of Disease in Childhood-Fetal and Neonatal Edition"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0088","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/jamapediatrics.2017.5323","article-title":"Cognitive outcomes of children born extremely or very preterm since the 1990s and associated risk factors: a meta-analysis and meta-regression","volume":"172","author":"Twilhaar","year":"2018","journal-title":"JAMA Pediatrics"},{"issue":"9","key":"10.1016\/j.survophthal.2021.02.012_bib0089","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/dmcn.14213","article-title":"Executive function deficits in children born preterm or at low birthweight: a meta-analysis","volume":"61","author":"van Houdt","year":"2019","journal-title":"Developmental Medicine & Child Neurology"},{"issue":"5","key":"10.1016\/j.survophthal.2021.02.012_bib0090","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2021.02.012_bib0091","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1978","article-title":"Trends in the screening and treatment of retinopathy of prematurity","volume":"139","author":"Vartanian","year":"2017","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.survophthal.2021.02.012_bib0092","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0093","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clp.2013.02.005","article-title":"Current and future trends in treatment of severe retinopathy of prematurity","volume":"40","author":"Wallace","year":"2013","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0094","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/EB.S94449","article-title":"Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy","volume":"8","author":"Wang","year":"2016","journal-title":"Eye Brain"},{"issue":"11 Supplement 3","key":"10.1016\/j.survophthal.2021.02.012_bib0095","first-page":"S54","article-title":"Cognition assessment using the NIH Toolbox","volume":"80","author":"Weintraub","year":"2013","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.survophthal.2021.02.012_bib0096","first-page":"822","article-title":"The test\u2013retest reliability of the latent construct of executive function depends on whether tasks are represented as formative or reflective indicators","volume":"23","author":"Willoughby","year":"2016","journal-title":"Child Neuropsychology"},{"issue":"1","key":"10.1016\/j.survophthal.2021.02.012_bib0097","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/87565641.2011.540530","article-title":"Neonatal white matter abnormalities predict global executive function impairment in children born very preterm","volume":"36","author":"Woodward","year":"2011","journal-title":"Dev Neuropsychol"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0098","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2021.02.012_bib0099","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2021.02.012_bib0100","article-title":"Bevacizumab for Retinopathy of Prematurity: 2-Year Neurodevelopmental Follow-up","author":"Zayek","year":"2020","journal-title":"Am J Perinatol"},{"issue":"1","key":"10.1016\/j.survophthal.2021.02.012_bib0101","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab","volume":"254","author":"Zhou","year":"2016","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2021.02.012_bib0102","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625721000667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625721000667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:53:34Z","timestamp":1758542014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625721000667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":102,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0039625721000667"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2021.02.012","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2021.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}